文献速递肾移植血液净化与透析

移植与血液透析中的精准医学

Precision medicine in transplantation and hemodialysis.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

本文综述精准医学在肾移植和血液透析中的应用现状。肾移植中HLA基因分型、供者特异性抗体检测、非HLA错配、免疫克隆追踪和转录组分析已用于个体化治疗;血液透析仍基于尿素清除率标准化处方,缺乏精准性,需识别其他尿毒症溶质。

要点

  • 肾移植精准医学已进入临床:HLA分型、DSA检测、非HLA错配评估和转录组分析可指导个体化治疗。
  • 血液透析处方远未精准:指南未考虑年龄、饮食和合并症,残余肾功能患者接受相同治疗。
  • Kt/Vurea不反映尿毒症症状严重程度或长期结局,尿素不能代表其他蓄积溶质。

核心结论

  • 肾移植领域精准医学已进入临床实践,而血液透析治疗处方仍远未精准。

研究设计与样本

  • 综述性文章,未报告系统检索范围或样本量。

主要发现

  • 肾移植中供受者HLA区域在2个class 1和通常3个class 2位点进行基因分型,并通过检测抗HLA供者特异性抗体评估致敏程度。
  • 非HLA错配与急性T细胞和B细胞介导排斥甚至长期移植物存活相关。
  • 通过下一代测序追踪特定同种免疫T和B细胞克隆,以及细化同种表位与HLA及T/B细胞受体相互作用的免疫原性,可能进一步支持个体化治疗。
  • 血液透析指南未考虑年龄、饮食或许多合并症对治疗的调整,有残余肾功能患者常规接受与无残余肾功能患者相同的治疗。
  • Kt/Vurea及相关参数既不反映尿毒症症状严重程度也不预测长期结局,尿素不能代表肾功能衰竭时体内蓄积的众多其他化合物。

关键数值与推荐

  • 肾移植中HLA基因分型涉及2个class 1和通常3个class 2位点。
  • 血液透析充分性定义基于尿素清除,Kt/Vurea及相关参数不反映尿毒症症状严重程度或预测长期结局。

临床怎么用

  • 肾移植中可根据HLA分型、DSA检测、非HLA错配和转录组分析等风险预测指标调整个体化免疫抑制剂量。
  • 血液透析需超越基于尿素测量的标准化处方,识别并测量导致特定尿毒症表现的 other 溶质。

局限性

  • 维持免疫抑制选择有限,个体化主要通过基于风险预测指标的剂量调整实现。
  • 血液透析精准处方的 major 障碍是 based on 尿素清除的「充分」治疗定义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In kidney transplantation, precision medicine has already entered clinical practice. Donor and recipient human leucocyte antigen (HLA) regions are genotyped in two class 1 and usually three class 2 loci, and the individual degree of sensitization against alloimmune antigens is evaluated by the detection of anti-HLA donor-specific antibodies. Recently, the contribution of non-HLA mismatches to outcomes such as acute T- and B-cell-mediated rejection and even long-term graft survival was described. Tracking of specific alloimmune T- and B-cell clones by next generation sequencing and refinement of the immunogenicity of allo-epitopes specifically in the interaction with HLA and T- and B-cell receptors may further support individualized therapy. Although the choices of maintenance immunosuppression are rather limited, individualization can be accomplished by adjustment of dosing based on these risk predictors. Finally, supplementing histopathology by a transcriptomics analysis allows for a biological interpretation of the histological findings and avoids interobserver variability of results. In contrast to transplantation, the prescription of hemodialysis therapy is far from precise. Guidelines do not consider modifications by age, diet or many comorbid conditions. Patients with residual kidney function routinely receive the same treatment as those without. A major barrier hitherto is the definition of 'adequate' treatment based on urea removal. Kt/Vurea and related parameters neither reflect the severity of uremic symptoms nor predict long-term outcomes. Urea is poorly representative for numerous other compounds that accumulate in the body when the kidneys fail, yet clinicians prescribe treatment based on its measurement. Modern technology has provided the means to identify other solutes responsible for specific features of uremic illness and their measurement will be a necessary step in moving beyond the standardized prescription of hemodialysis.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Oberbauer R, Meyer TW. Precision medicine in transplantation and hemodialysis. Nephrol Dial Transplant. 2021. PMID: 34153984. doi:10.1093/ndt/gfaa367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。